Health-related quality of life (HRQoL), anxiety, and depression in patients with desmoid type fibromatosis

• Published in: Supportive care in cancer Vol. 30; no. 12; pp. 10089 - 10098
• Main Authors: Garg, Vikas, Rastogi, Sameer, Kalra, Kaushal, Bhoriwal, Sandeep, Barwad, Adarsh, Dhamija, Ekta, Upadhyay, Ashish, Gamangatti, Shivanand
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2022; Springer; Springer Nature B.V
• Subjects: Anxiety; Cancer; Connective tissue diseases; Emotions; Health; Inhibitor drugs; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Mental depression; Nursing; Nursing Research; Oncology; Pain Medicine; Quality of life; Rehabilitation Medicine; Tumors; Health-related quality of life; Desmoid; DTF; HRQoL; Depression; Anxiety; Patient-reported outcomes; Fibromatosis
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-022-07445-0

Introduction Data on the impact of desmoid type fibromatosis (DTF) on emotional distress and health-related quality of life (HRQoL) is sparse. Methodology In this prospective cross-sectional study, patients with DTF and healthy controls were asked to fill the EORTC QLQ-C30, GAD-7, and PHQ-9 questionnaires. The objectives were to determine HRQoL, anxiety, and depression in patients with DTF. Results Two hundred four subjects (102 DTF patients and 102 healthy controls) were recruited. The median age of DTF patients at recruitment into the study was 31 years (IQR, 25–37 years). There was a female preponderance with a male:female ratio of 1:1.83. Appendicular skeleton and abdomen sites were most commonly involved in 59% and 22.5% respectively. About half (54%) of patients were currently on sorafenib and 41% were under active surveillance. The mean global health status in DTF patients was 65.58 ± 22.64, significantly lower than healthy controls. Similarly, DTF patients scored low on all functional scales except cognitive functioning. The symptom scale showed a significantly higher symptom burden of fatigue, pain, insomnia, and financial difficulties. Anxiety and depression was observed in 39.22% and 50% of DTF patients respectively. DTF patients had higher rates of mild, moderate, and severe anxiety and depression compared to healthy controls. Conclusion DTF patients have significant symptom burden, poor functioning, and heightened anxiety and depression as compared to healthy controls. HRQoL, anxiety, and depression should be routinely used to assess symptom burden and treatment efficacy in DTF patients.